Alzheimer: High Health Authority Refuses Accelerated Approval Procedure for Leqembi Treatment

Sud Ouest

Center

Factuality

Ownership

High Health Authority expresses reservations about the efficacy and tolerance of Leqembi, an anti-Alzheimer drug with high hopes The High Health Authority (HAS) issued on Tuesday

Le Point.fr

Lean Right

Factuality

Ownership

The Leqembi (lecanemab) will not benefit from a precocious access to the French march, which is not very effective, very expensive and has an undesirable and preoccupying effect.

Le Huffington Post

Left

Factuality

Ownership

Within the medical world, the precautions of the High Health Authority have given rise to contrasting reactions, between convinced and skeptical of this new treatment.

Liberation

Lean Left

Factuality

Ownership

The independent health authority concludes that there is a small benefit to Alzheimer's treatment in early access but that there is a high risk of serious side effects.

Le Parisien

Lean Right

Factuality

Ownership

The High Health Authority (HAS) today voted against the immediate repayment of Leqembi, a medicine against Alzheimer's disease authorised on the European market since the end of last year.

elle.fr

Factuality

Ownership

Leqembi, a new treatment for Alzheimer's disease, will not be reimbursed immediately in France. His High Health Authority (HAS) is skeptical, evoking side effects that are far too heavy in view of the insignifica... Read more about Elle.fr